A randomised controlled trial of Myfortic versus Mycophenolate Mofetil in the treatment of multi-system autoimmune disease. - MYFMAD

Cambridge University Hospitals NHS Foundation Trust0 个研究点目标入组 40 人开始时间: 2005年8月16日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•Inclusion (requires all three)
•i)Diagnosis of SLE or PSV
•ii)Either: about to commence MMF, or established on MMF for at least three months but with inadequate disease control on MMF 2000mg/day or less
•iii)Written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•b)Exclusion
•i)Active infection (including hepatitis B, C, HIV and tuberculosis)
•ii)Known hypersensitivity to MMF
•iii)cancer or an individual history of cancer (other than resected basal cell skin carcinoma)
•iv)Females who are pregnant, breast feeding, or at risk of pregnancy and not using a medically acceptable form of contraception
•v)Any condition judged by the investigator that would cause the study to be detrimental to the patient
•vi)Use of any investigational drug within four weeks of the baseline visit
•vii)Patients who are planning to undergo elective surgery during the study period
•viii)Age < 18 years

发起方